Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM) | MicrobiomeTrials← Back to trialsNCT07237399
Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM)
WITHDRAWNOBSERVATIONAL
Trial Details
Start: 2026-05-10Est. Completion: 2031-04-01
Enrollment target: 0 participants Locations- Ghent University Hospital, Ghent, Belgium
Other microbiome trials you might be interested in
Oligometastatic Prostate Cancer (OMPC)
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in p…
Fayetteville, United StatesEst. completion Apr 25, 2028
Prostate Cancer Metastatic DiseaseOligometastatic Prostate Cancer (OMPC)
The investigators propose redefining this concept by focusing on volume rather than the number of metastases. To achieve…
Saint-Herblain, FranceEst. completion May 1, 2028